Evidence map›Paper›PMID 41634518›Full record

ArticleAnnals of surgical oncology2026

Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases.

Princy Gupta, Elizabeth L Godfrey, Kurt S Schultz, Lu Qiao, Nicole Aguirre, Justin M Bader, Michael B Foote, John Paul Shen, Ardaman P Shergill, Michael Cecchini and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Princy GuptaDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Elizabeth L GodfreyDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Kurt S SchultzDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Lu QiaoDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Nicole AguirreDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Justin M BaderDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Michael B FooteDivision of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
John Paul ShenDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ardaman P ShergillSection of Hematology/Oncology, Department of Internal Medicine, University of Chicago, Chicago, IL, USA.
Michael CecchiniDepartment of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
Raghav SundarDepartment of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
Jason M SheltzerDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Kiran K TuragaDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA. kiran.turaga@yale.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough hyperthermic intraperitoneal chemotherapy (HIPEC) added to cytoreductive surgery shows promise for colorectal cancer with peritoneal metastases (CRC-PM), effectiveness remains variable. Given the predominance of consensus molecular subtype 4 (CMS4) in CRC-PM and resistance to standard agents, we hypothesized CMS4 exhibits distinct drug sensitivities. MATERIALS AND

methodsDrug sensitivity data from the DepMap PRISM Repurposing Dataset for 34 CRC cell lines were classified into the 4 CMS subtypes. Five intraperitoneal agents were analyzed: mitomycin-C, oxaliplatin, irinotecan, 5-fluorouracil, and cisplatin. Differential drug response among CMS subtypes was assessed using log2 fold change (log2FC) in cell viability.

resultsThe 34 CRC cell lines were classified into 4 categories: CMS1 (29%), CMS2 (18%), CMS3 (26%), and CMS4 (26%). CMS4 cell lines demonstrated higher sensitivity than CMS2 lines to mitomycin-C (median log2FC = -2.35 versus -0.21, p = 0.019). CMS4 and CMS3 cell lines were significantly more sensitive to irinotecan than CMS1 and CMS2 cell lines (p = 0.004). Oxaliplatin, 5-fluorouracil, and cisplatin showed no differential sensitivity across subtypes. CMS4 cell lines demonstrated sensitivity (sensitivity threshold log2FC < -1.74) to mitomycin-C and irinotecan but showed lack of sensitivity to oxaliplatin, 5-fluorouracil, and cisplatin.

conclusionsCMS4 exhibits distinct drug sensitivity patterns that could guide personalized HIPEC agent selection. This may explain the success of mitomycin-C and the limited efficacy of oxaliplatin in HIPEC trials. Future clinical trials should consider genomic subtyping and drug sensitivity testing to guide personalized HIPEC strategies for patients with CRC-PM.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorColorectal NeoplasmsHyperthermia, InducedHyperthermic Intraperitoneal ChemotherapyPeritoneal NeoplasmsCisplatinDrug Resistance, NeoplasmFluorouracilHumansIrinotecanMitomycinOxaliplatinPrognosisTumor Cells, CulturedBiomarkers, TumorCisplatinFluorouracilIrinotecanMitomycinOxaliplatinColorectal cancerConsensus molecular subtypesHyperthermic intraperitoneal chemotherapyMitomycin-COxaliplatinPeritoneal metastases

Identifiers

PMID41634518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.